Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 34309669)

  • 1. Correlation Between Surrogate End Points and Overall Survival in a Multi-institutional Clinicogenomic Cohort of Patients With Non-Small Cell Lung or Colorectal Cancer.
    Kehl KL; Riely GJ; Lepisto EM; Lavery JA; Warner JL; LeNoue-Newton ML; Sweeney SM; Rudolph JE; Brown S; Yu C; Bedard PL; Schrag D; Panageas KS;
    JAMA Netw Open; 2021 Jul; 4(7):e2117547. PubMed ID: 34309669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intracranial and Extracranial Progression and Their Correlation With Overall Survival After Stereotactic Radiosurgery in a Multi-institutional Cohort With Brain Metastases.
    Carpenter DJ; Leng J; Arshad M; Giles W; Kirkpatrick JP; Floyd SR; Chmura SJ; Salama JK; Hong JC
    JAMA Netw Open; 2023 Apr; 6(4):e2310117. PubMed ID: 37099292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of time-to-treatment discontinuation of targeted therapy, immunotherapy, and chemotherapy in clinical trials of patients with non-small-cell lung cancer.
    Blumenthal GM; Gong Y; Kehl K; Mishra-Kalyani P; Goldberg KB; Khozin S; Kluetz PG; Oxnard GR; Pazdur R
    Ann Oncol; 2019 May; 30(5):830-838. PubMed ID: 30796424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterizing the Feasibility and Performance of Real-World Tumor Progression End Points and Their Association With Overall Survival in a Large Advanced Non-Small-Cell Lung Cancer Data Set.
    Griffith SD; Miksad RA; Calkins G; You P; Lipitz NG; Bourla AB; Williams E; George DJ; Schrag D; Khozin S; Capra WB; Taylor MD; Abernethy AP
    JCO Clin Cancer Inform; 2019 Aug; 3():1-13. PubMed ID: 31403818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non-Small Cell Lung Cancer Using a Clinicogenomic Database.
    Singal G; Miller PG; Agarwala V; Li G; Kaushik G; Backenroth D; Gossai A; Frampton GM; Torres AZ; Lehnert EM; Bourque D; O'Connell C; Bowser B; Caron T; Baydur E; Seidl-Rathkopf K; Ivanov I; Alpha-Cobb G; Guria A; He J; Frank S; Nunnally AC; Bailey M; Jaskiw A; Feuchtbaum D; Nussbaum N; Abernethy AP; Miller VA
    JAMA; 2019 Apr; 321(14):1391-1399. PubMed ID: 30964529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and Validation of a Machine Learning Model to Explore Tyrosine Kinase Inhibitor Response in Patients With Stage IV EGFR Variant-Positive Non-Small Cell Lung Cancer.
    Song J; Wang L; Ng NN; Zhao M; Shi J; Wu N; Li W; Liu Z; Yeom KW; Tian J
    JAMA Netw Open; 2020 Dec; 3(12):e2030442. PubMed ID: 33331920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distribution of ALK Fusion Variants and Correlation with Clinical Outcomes in Chinese Patients with Non-Small Cell Lung Cancer Treated with Crizotinib.
    Su Y; Long X; Song Y; Chen P; Li S; Yang H; Wu P; Wang Y; Bing Z; Cao Z; Cao L; Wu Y; Zhang Z; Liu J; Li B; Xiang J; Ma K; Zhang T; Zhang L; Mao X; Liu H; Xing P; Liang N
    Target Oncol; 2019 Apr; 14(2):159-168. PubMed ID: 30895431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progression-free survival and one-year milestone survival as surrogates for overall survival in previously treated advanced non-small cell lung cancer.
    Zhao S; Zhang Z; Zhang Y; Hong S; Zhou T; Yang Y; Fang W; Zhao H; Zhang L
    Int J Cancer; 2019 Jun; 144(11):2854-2866. PubMed ID: 30430561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Tumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation With Response to Immune Checkpoint Inhibitors and Mortality in Patients With Non-Small Cell Lung Cancer.
    Chen Y; Chen G; Li J; Huang YY; Li Y; Lin J; Chen LZ; Lu JP; Wang YQ; Wang CX; Pan LK; Xia XF; Yi X; Chen CB; Zheng XW; Guo ZQ; Pan JJ
    JAMA Netw Open; 2019 Sep; 2(9):e1911895. PubMed ID: 31539077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating Expected Costs and Benefits of Granting Access to New Treatments on the Basis of Progression-Free Survival in Non-Small-Cell Lung Cancer.
    Lakdawalla DN; Chou JW; Linthicum MT; MacEwan JP; Zhang J; Goldman DP
    JAMA Oncol; 2015 May; 1(2):196-202. PubMed ID: 26181023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meta-analyses of randomized controlled trials show suboptimal validity of surrogate outcomes for overall survival in advanced colorectal cancer.
    Ciani O; Buyse M; Garside R; Peters J; Saad ED; Stein K; Taylor RS
    J Clin Epidemiol; 2015 Jul; 68(7):833-42. PubMed ID: 25863582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of Progression-Free Survival as a Surrogate End Point of Overall Survival in First-Line Treatment of Ovarian Cancer: A Systematic Review and Meta-analysis.
    Paoletti X; Lewsley LA; Daniele G; Cook A; Yanaihara N; Tinker A; Kristensen G; Ottevanger PB; Aravantinos G; Miller A; Boere IA; Fruscio R; Reyners AKL; Pujade-Lauraine E; Harkin A; Pignata S; Kagimura T; Welch S; Paul J; Karamouza E; Glasspool RM;
    JAMA Netw Open; 2020 Jan; 3(1):e1918939. PubMed ID: 31922558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A methodology to extract outcomes from routine healthcare data for patients with locally advanced non-small cell lung cancer.
    Wong SL; Ricketts K; Royle G; Williams M; Mendes R
    BMC Health Serv Res; 2018 Apr; 18(1):278. PubMed ID: 29642889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of High-Dose vs Standard-Dose Vitamin D3 Supplementation on Progression-Free Survival Among Patients With Advanced or Metastatic Colorectal Cancer: The SUNSHINE Randomized Clinical Trial.
    Ng K; Nimeiri HS; McCleary NJ; Abrams TA; Yurgelun MB; Cleary JM; Rubinson DA; Schrag D; Miksad R; Bullock AJ; Allen J; Zuckerman D; Chan E; Chan JA; Wolpin BM; Constantine M; Weckstein DJ; Faggen MA; Thomas CA; Kournioti C; Yuan C; Ganser C; Wilkinson B; Mackintosh C; Zheng H; Hollis BW; Meyerhardt JA; Fuchs CS
    JAMA; 2019 Apr; 321(14):1370-1379. PubMed ID: 30964527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer.
    Nakagawa K; Hida T; Nokihara H; Morise M; Azuma K; Kim YH; Seto T; Takiguchi Y; Nishio M; Yoshioka H; Kumagai T; Hotta K; Watanabe S; Goto K; Satouchi M; Kozuki T; Koyama R; Mitsudomi T; Yamamoto N; Asakawa T; Hayashi M; Hasegawa W; Tamura T
    Lung Cancer; 2020 Jan; 139():195-199. PubMed ID: 31812890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Performance Status With Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy.
    Sehgal K; Gill RR; Widick P; Bindal P; McDonald DC; Shea M; Rangachari D; Costa DB
    JAMA Netw Open; 2021 Feb; 4(2):e2037120. PubMed ID: 33570575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of high PD-L1 expression on the surrogate endpoints and clinical outcomes of anti-PD-1/PD-L1 antibodies in non-small cell lung cancer.
    Ito K; Miura S; Sakaguchi T; Murotani K; Horita N; Akamatsu H; Uemura K; Morita S; Yamamoto N
    Lung Cancer; 2019 Feb; 128():113-119. PubMed ID: 30642442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Verification of the correlation between progression-free survival and overall survival considering magnitudes of survival post- progression in the treatment of four types of cancer.
    Liu LY; Yu H; Bai JL; Zeng P; Miao DD; Chen F
    Asian Pac J Cancer Prev; 2015; 16(3):1001-6. PubMed ID: 25735320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.